OBJECTIVES : Flash Glycose Monitoring (FGM) is an innovative technology for glucose control that helps patients to avoid hypoglycemias and remain within Time in Range. Currently, only patients with DM1 are covered for using FGM by the National Organization for the Provision of Healthcare (EOPYY). Thus, we evaluated the economic consequences of FGM reimbursement expansion:a) in DM2 patients subjected to intensive insulin (N≥3 injections daily) b) in all insulin-treated patients with DM2

METHODS : A Budget Impact Analysis Model (ΒΙΑM) was used, with a time horizon of three years. Resource utilization included the cost of all non-durables in regards to self-glycose monitoring and the cost of management of severe and non-severe hypoglycemia events. Analyses were conducted from the EOPYY perspective, taking into consideration a novel reimbursement model of progressive volume based price deduction for sensor and zero price for reader (as it is provided free of charge)

RESULTS : In the case of simultaneous coverage of FGM for both DM1 and DM2 patients, savings result from the very first year, increasing with the increase of the number of beneficiaries and peak during the third year. Specifically, savings reach the amount of a) € 1.9 million in the case of coverage of intensive insulin DM1 and DM2 patients and b) € 0.78 million in the case of coverage of all patients under insulin. The cumulative savings over three years amount to € 3.266 million for case (a) and € 1.3 million for case (b)

CONCLUSIONS : Given the reduction of severe and non-severe hypoglycemia events for patients using the FGM technology, when compared with the SMBG (based on the relevant literature), and consequently, the cost savings achieved for EOPYY, the FGM technology is considered as of high value and, thus, the expansion of reimbursement coverage to DM2 patients is recommended.